TXNIP and type 2 diabetes mellitus: Within an incident T2D case–cohort study nested within the population-based EPIC-Norfolk study, a prospective cohort study recruiting 25,639 individuals, Cardona et al. [220] confirmed the results of [199], identifying 18 methylation variable positions in whole blood strongly associated with incident T2D, of which the most robust involved TXNIP (decreased methylation), ABCG1, and SREBF1 (both increased methylation).